New model developed

HUB Organoids® to evaluate epithelial barrier function

Compromised intestinal barrier function has been associated with a number of intestinal and systemic diseases, including inflammatory bowel disease (IBD), obesity, metabolic disorders, and graft versus host disease. Limited approved agents that target the intestinal epithelial barrier integrity are presently available for IBD due also to the lack of predictive and physiologically relevant preclinical models. Our new published paper discusses the development of a new HUB organoids-based model to assess drug efficacy and safety, as well as absorption, metabolism, transport and permeability.

Read this paper to:

  • Learn about the establishment of intestinal organoid-derived epithelial monolayers
  • Discover how they can be applied to measuring epithelial barrier integrity, permeability, transport, as well as antimicrobial protein secretion
  • Find out how to study the effects and mode of action of your compound on target cells by enriching organoid monolayers with key differentiated epithelial cells

read more

Discover more from HUB:

Epithelial barrier function assay

Determine the effect of your compound on epithelial barrier function, integrity, and tight cell junction dynamics in patient-derived organoids

discover more

Discover our IBD biobank

Explore our wide range of patient-derived organoid models from colon and small intestine biopsies of IBD patients

discover our biobank

PDO Screen

Enroll in our cost-effective drug screening platform and receive a quick read out of your drug’s efficacy and safety in patient-derived organoids

enroll now